VERU INC. (VERU) AI Stock Summary

Snapshot

Veru is a clinical-stage biopharma that reported $0 in revenue for fiscal 2025 (down from $16.9M the prior year) and a $22.7M net loss, burning roughly $30M in cash from operations. It ended the year with $18.3M in cash against that burn rate, giving a runway of about 8.3 months, tight by any standard. The stock trades near its 52-week low.

What's Happening Right Now

• Mon 10th Aug '26 · Earnings: Fiscal Q3 net loss narrowed to $7.0M ($0.30/share) and cash rose to $23.9M, while the Phase 2b PLATEAU obesity trial finished enrolling 239 patients with interim results due Q1 2027.
• Tue 4th Aug '26 · Patent: Veru received a USPTO Notice of Allowance for a patent covering enobosarm combined with semaglutide for weight loss, giving protection until at least October 2044 once issued.
• Mon 27th Jul '26 · Trial update: Veru announced full enrollment (about 200+ patients) in its Phase 2b PLATEAU study testing enobosarm plus semaglutide for weight loss in older adults, with final topline data expected Q4 2027.

Ownership

Institutions hold 25.5% of shares, insiders hold 0.2%.

Bottom Line

Veru is a research-stage company with no product revenue left, a shrinking cash pile, and roughly eight months of runway at its current burn rate. The pending patent and the fully enrolled weight-loss trial are real pipeline milestones, but interim data isn't due until early 2027, well beyond the current cash horizon. A reader looking at this name should understand it as a bet on the company raising more money or getting positive trial data before cash runs low, not a financially stable business today.